From bench to bedside?preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A), J. Inorg. Biochem, vol.100, pp.891-904, 2006. ,
Non-Platinum Chemotherapeutic Metallopharmaceuticals, Chem. Rev, vol.99, 1999. ,
Ruthenium metallopharmaceuticals, Coord. Chem. Rev, vol.236, pp.209-233, 2003. ,
Structure?activity relationships for ruthenium and osmium anticancer agents ? towards clinical development, Chem. Soc. Rev, vol.47, pp.909-928, 2018. ,
, vivo anti-tumor activity of the organometallic ruthenium(II)-arene complex, vol.5, pp.4742-4748, 2014.
Ruthenium complexes as anticancer agents, Curr. Med. Chem, vol.13, pp.1085-1107, 2006. ,
Ruthenium-based chemotherapeutics: are they ready for prime time?, Cancer Chemother. Pharmacol, vol.66, pp.1-9, 2010. ,
Ligand substitutions between ruthenium?cymene compounds can control protein versus DNA targeting and anticancer activity, Nat. Commun, vol.5, p.3462, 2014. ,
Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action, Chem. Sci, vol.6, pp.2449-2456, 2015. ,
In Vitro Evaluation of Rhodium and Osmium RAPTA Analogues: The Case for Organometallic Anticancer Drugs Not Based on Ruthenium, Organometallics, vol.25, pp.4090-4096, 2006. ,
Opening the lid on piano-stool complexes: An account of ruthenium(II)?arene complexes with medicinal applications, J. Organomet. Chem, vol.751, pp.251-260, 2014. ,
Arene ruthenium complexes as anticancer agents ,
, Dalton Trans, pp.39-1673, 2010.
Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes, Chem. Commun, pp.4764-4776, 2005. ,
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes, J. Med. Chem, vol.48, pp.4161-4171, 2005. ,
Inhibition of cancer cell growth by ruthenium(II) arene complexes, J. Med. Chem, vol.44, pp.3616-3621, 2001. ,
Maltol-Derived Ruthenium?Cymene Complexes with Tumor Inhibiting Properties: The Impact of Ligand?Metal Bond Stability on Anticancer Activity In Vitro, Chem. -Eur. J, vol.15, pp.12283-12291, 2009. ,
Anticancer Ruthenium(? 6 -p-cymene) Complexes of Nonsteroidal Anti-inflammatory Drug Derivatives, Organometallics, vol.33, pp.5546-5553, 2014. ,
Electron-transfer activated metal-based anticancer drugs, Inorg. Chim. Acta, vol.361, pp.1569-1583, 2008. ,
Pyrone derivatives and metals: From natural products to metal-based drugs, J. Organomet. Chem, vol.696, pp.999-1010, 2011. ,
Organometallic anticancer complexes of lapachol: Metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity, Chem. Commun, vol.49, pp.3348-3350, 2013. ,
Synthesis, Characterization, and Cytotoxic Activity of AuI N, S-Heterocyclic Carbenes Derived from Peptides Containing L-Thiazolylalanine, Eur. J. Inorg. Chem, pp.2512-2519, 2014. ,
NHC ligands versus cyclopentadienyls and phosphines as spectator ligands in organometallic catalysis, J. Organomet. Chem, vol.690, pp.5451-5457, 2005. ,
The development of L 2 X 2 Ru CHR olefin metathesis catalysts: an organometallic success story, Acc. Chem. Res, vol.34, pp.18-29, 2001. ,
Heterocyclic carbene metal complexes in medicinal chemistry, Dalton Trans, vol.42, pp.3269-3284, 2013. ,
Ott, I. TrxR inhibition and antiproliferative activities of structurally diverse gold N-heterocyclic carbene complexes, MedChemComm, vol.4, pp.942-948, 2013. ,
Synthesis, cytotoxic and antibacterial studies of p-benzyl-substituted NHC?silver(I) acetate compounds derived from 4, 5-di-p-diisopropylphenyl-or 4, 5-di-p-chlorophenyl-1H-imidazole, J. Organomet. Chem, vol.749, pp.88-99, 2014. ,
Biscarbene gold(I) complexes: structure?activity-relationships regarding antibacterial effects, cytotoxicity, TrxR inhibition and cellular bioavailability, vol.8, pp.1681-1689, 2017. ,
From catalysts to bioactive organometallics: do Grubbs catalysts trigger biological effects, ChemMedChem, 2011. ,
Evaluation of arene ruthenium(II) Nheterocyclic carbene complexes as organometallics interacting with thiol and selenol containing biomolecules, Dalton Trans, vol.42, pp.1657-1666, 2013. ,
On the binding modes of metal NHC complexes with DNA secondary structures: implications for therapy and imaging, Chem. Commun, vol.53, pp.8249-8260, 2017. ,
Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis (2-amino-5-methylthiazole) tetrachlororuthenate (III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound, J. Med. Chem, vol.50, pp.5871-5874, 2007. ,
Cytotoxicity and Antibacterial Studies of p-Methoxybenzyl-Substituted and Benzyl-Substituted N-Heterocyclic Carbene?Silver Complexes, Eur. J. Inorg. Chem, pp.1020-1031, 2010. ,
,
, -para-cymene)iodoruthenium(II)] toluene solvate, Acta Crystallogr., Sect. C: Cryst. Struct. Commun, vol.55, issue.6, 1999.
Mechanism of Formation of silver N-Heterocyclic Carbenes using Silver Oxide: a Theoretical Study, Organometallics, vol.26, pp.6170-6183, 2007. ,
-Hexamethylbenzene) Ruthenium Complexes, Inorganic Syntheses ,
, , vol.21, pp.74-78, 2007.
New (carbene) ruthenium-arene complexes: preparation and uses in catalytic synthesis of furans, Organometallics, vol.15, pp.2434-2439, 1996. ,
Deactivation of a ruthenium(II) N-heterocyclic carbene p-cymene complex during transfer hydrogenation catalysis, Transition Met. Chem, vol.43, pp.21-29, 2018. ,
Novel metal(II) arene 2-pyridinecarbothioamides: A rationale to orally active organometallic anticancer agents, Chem. Sci, vol.4, pp.1837-1846, 2013. ,
Selective hydrogenation of levulinic acid to [gamma]-valerolactone using in situ generated ruthenium nanoparticles derived from Ru-NHC complexes, Dalton Trans, vol.45, pp.3558-3563, 2016. ,
Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity, Proc. Natl. Acad. Sci. U. S. A, vol.102, pp.18269-18274, 2005. ,
Organometallic Osmium Arene Complexes with Potent Cancer Cell Cytotoxicity, J. Med. Chem, pp.8192-8196, 2010. ,
Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms, J. Am. Chem. Soc, vol.125, pp.173-186, 2003. ,
Characterizing activation mechanisms and binding preferences Inorganic Chemistry Article ,
, Inorg. Chem, vol.57, pp.14427-14434, 2018.
, of ruthenium metallo-prodrugs by a competitive binding assay, J. Inorg. Biochem, vol.177, pp.322-327, 2017.
DNA or protein? Capillary zone electrophoresis-mass spectrometry rapidly elucidates metallodrug binding selectivity, Chem. Commun, vol.53, pp.8002-8005, 2017. ,
Unexpected arene ligand exchange results in the oxidation of an organoruthenium anticancer agent: the first X-ray structure of a protein-Ru(carbene) adduct, Chem. Commun, vol.54, pp.6120-6123, 2018. ,
Crystal structure and catalysis of the selenoprotein thioredoxin reductase 1, J. Biol. Chem, p.3998, 2009. ,
Bioinorganic and medicinal chemistry: aspects of gold (I)-protein complexes, Dalton Transactions, vol.40, 2011. ,
Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent, Eur. J. Med. Chem, vol.140, pp.435-447, 2017. ,